living
immunotherapies 

We are empowering T cells to effectively fight cancer. 

Immunotherapies show great promise to revolutionize cancer treatment. Therefore, we put living T cells - key players in the immune system - at the center of our technology platforms. We are striving to create breakthrough therapies to fundamentally improve the lives of cancer patients.

Latest News

Medigene announces capital increase to fund immunotherapy programs

SHOW RELEASE

Medigene reports outcome of Annual General Meeting

SHOW RELEASE

Medigene significantly expands TCR alliance with bluebird bio in cancer immunotherapy

SHOW RELEASE

Fighting cancer with cutting-edge technologies

The therapeutic potential of human T cells can radically change the future of cancer treatment. Medigene uses its proprietary platform technologies to modify T cells for the fight against tumor cells, thereby activating the body’s own immune defense mechanisms.

TCR-Ts

Generating large numbers of cancer-specific T cells to recognize and kill cancer cells. 

MORE ABOUT TCR-Ts

DCs

An entirely new generation of DC vaccines being developed.

MORE ABOUT DCs

TABs

Developing monoclonal antibodies to recognize T cells.

MORE ABOUT TABs

Deeply rooted in Science

Our deep scientific expertise is rooted in decades of immunological research by Prof. Dr. Dolores J. Schendel and her team.

More about our expertise

Capacity to innovate

The cumulated scientific knowledge and experience of our scientists, allied with high-throughput automation technologies, accelerate the discovery and development process for new therapies.

MORE ABOUT OUR INNOVATIONs

Growing pipeline

Our first TCR-T therapy MDG1011 has entered clinical development, augmenting the proprietary clinical-stage DC vaccines. We aim to fill our immunotherpy pipeline of with more natural TCR-Ts and prepare them for clinical development.

More about our Pipeline

Nimble and efficient

At Medigene, we combine state-of-the-art science and an entrepreneurial start-up culture within the structures of an established biopharmaceutical company. 

MORE ABOUT OUR COMPANY

MDG1

Listed on the Frankfurt Stock Exchange, TecDAX, WKN: A1X3W

> 90

Headquartered in Munich, Germany and with an office in San Diego, USA, actually over 90 employees

+29%

Increase in Research & Development expenses for immunotherapies in Q1 2018, compared to previous year.

Partner-like

Medigene has developed several clinical stage drugs, ranging from the research phase to commercialization and product launch onto the market. In cooperation with partners, we intend to become a global leader in the field of T cell immunotherapies.

MORE ABOUT OUR PARTNERS

“Medigene is one of the few companies worldwide with a TCR-T based immunotherapy in clinical development.
In 2018, we will collect initial data on safety and tolerability of this innovative cancer therapy .”
Dolores Schendel, CEO

Living immuno­therapies, together

Our highly qualified scientists are dedicated to working at the forefront of cancer immunotherapies. Working closely with our experienced business specialists, they jointly develop highly innovative and effective therapies in order to help patients with severe illnesses.

More about career